An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Trial Profile

An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 04 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Mar 2014 Planned End Date changed from 1 Sep 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 02 Nov 2013 Findings will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, according to a Gilead Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top